Bacteriostatic Water · Research brief

How to Use Melanotan-2 for Tanning Protocol — Safe Dosing

Real Peptides Research TeamEditorial

Updated April 15, 20269 min read

54 WORDS

Short answer

Most people who start Melanotan-2 (MT-II) expect immediate tanning within days of their first injection. What actually happens: melanocortin-1 receptor activation without pigment production, followed by confusion about why nothing's changing. MT-II is an alpha-melanocyte-stimulating hormone (α-MSH) analogue that binds to MC1R receptors on melanocytes, triggering a cascade that prepares cells for eumelanin synthesis.

Key takeaways

Melanotan-2 activates melanocortin-1 receptors (MC1R) on melanocytes, which upregulates tyrosinase enzyme production. But melanin synthesis only occurs when those primed cells are exposed to UV radiation 4–6 hours post-injection.
Reconstitute lyophilised MT-II with bacteriostatic water at 1mg/mL concentration, store at 2–8°C, and use within 30 days to prevent peptide degradation and bacterial contamination.
The standard loading phase is 0.25–0.5mg injected subcutaneously daily for 5–7 days, followed by maintenance dosing at 0.5–1mg twice weekly to sustain pigmentation without daily injections.
Begin UV exposure on day 4 of loading, limiting initial sessions to 10–15 minutes to assess photosensitivity. MT-II amplifies melanogenesis but also increases the risk of erythema if UV exposure exceeds skin tolerance.
Nausea occurs in approximately 40% of users at doses above 0.5mg due to off-target MC4R activation in the hypothalamus; it typically resolves within 72 hours as receptors downregulate.

We've worked with researchers studying melanogenesis pathways for years. The gap between doing MT-II protocols correctly and wasting both peptide and UV exposure comes down to three things most guides ignore: reconstitution sterility, dose titration to avoid nausea, and UV timing relative to injection cycles.

How do you use Melanotan-2 for tanning protocol safely?

To use Melanotan-2 for tanning protocol, reconstitute lyophilised MT-II with bacteriostatic water at 1mg/mL concentration, inject 0.25–0.5mg subcutaneously daily for 5–7 days during the loading phase, then transition to 0.5–1mg twice weekly for maintenance while exposing skin to controlled UV (10–15 minutes per session starting 4–6 hours post-injection). The peptide primes melanocytes for pigment synthesis; tanning requires concurrent UV exposure.

The common mistake is treating MT-II like a standalone tanning agent. It's not. The peptide activates MC1R signalling, which upregulates tyrosinase. The enzyme that converts L-tyrosine into melanin precursors. Without UV photon energy to complete that conversion, you end up with receptor activation but no visible pigmentation. This article covers exact reconstitution protocols, dosing schedules that minimise nausea, UV exposure timing windows, and what happens when MT-II is used without proper phototherapy planning.

Step 1: Reconstitute Melanotan-2 with Bacteriostatic Water at 1mg/mL

Reconstitution sterility determines whether your peptide degrades before you finish the vial. MT-II arrives as a lyophilised powder. A freeze-dried cake of peptide molecules stabilised in the absence of water. Once you add bacteriostatic water, the peptide is active but vulnerable to bacterial contamination and temperature-induced denaturation. Standard reconstitution is 1mg peptide per 1mL bacteriostatic water (0.9% benzyl alcohol), which allows precise 0.1mL (100mcg) dose increments using an insulin syringe.

Allow the lyophilised vial to reach room temperature (20–22°C) for 15 minutes before reconstitution. Injecting cold bacteriostatic water into a cold vial creates condensation inside the stopper, increasing contamination risk. Swab the rubber stopper with 70% isopropyl alcohol and allow it to air-dry for 30 seconds. Inject bacteriostatic water slowly down the inside wall of the vial, not directly onto the peptide cake. Direct injection fractures the peptide structure. Gently roll the vial between your palms; do not shake. Shaking introduces air bubbles that denature peptide bonds at the air-liquid interface.

Store reconstituted MT-II at 2–8°C (standard refrigerator temperature) and use within 30 days. Every needle puncture through the stopper increases contamination risk. Draw your dose, remove the needle, and immediately return the vial to refrigeration. Do not leave reconstituted peptide at room temperature for more than 10 minutes. Temperature excursions above 8°C cause irreversible aggregation of peptide chains, reducing potency without visible indication.

Step 2: Begin Loading Phase at 0.25–0.5mg Daily for 5–7 Days

The loading phase saturates melanocortin receptors before introducing UV exposure. MT-II has a half-life of approximately 33 minutes in plasma but remains bound to MC1R receptors for 6–8 hours, creating a delayed effect window. Starting at 0.25mg daily (0.25mL of 1mg/mL solution) allows receptor binding without oversaturating, which reduces the incidence of nausea. The most common adverse effect during MT-II initiation.

Inject subcutaneously into abdominal fat, rotating sites daily to prevent lipohypertrophy (localised fat buildup at injection sites). Pinch a fold of skin, insert the needle at a 45-degree angle, aspirate to confirm you're not in a blood vessel, then inject slowly over 5 seconds. Rapid injection increases localised burning sensation. Most users tolerate 0.25mg without nausea; if well-tolerated after 48 hours, increase to 0.5mg daily for days 3–7.

Gastrointestinal effects. Nausea, reduced appetite, mild cramping. Occur in approximately 40% of users at doses above 0.5mg and peak 2–4 hours post-injection. This is MC4R activation in the hypothalamus (an off-target effect of MT-II, which has lower selectivity than endogenous α-MSH). Nausea typically resolves within 72 hours as MC4R receptors downregulate. If nausea persists beyond day 3, reduce dose to 0.25mg and extend loading phase to 10 days rather than increasing dose.

Do not introduce UV exposure during the first 3 days of loading. Melanocytes require 48–72 hours of sustained MC1R signalling to upregulate tyrosinase and prepare for melanogenesis. UV exposure before receptor saturation produces erythema (redness) without tanning because melanocytes lack the enzymatic capacity to synthesise protective melanin in response to photon damage.

Step 3: Introduce Controlled UV Exposure 4–6 Hours Post-Injection

Timing UV exposure relative to MT-II injection determines whether you tan or burn. MC1R signalling peaks 4–6 hours after subcutaneous injection, which is the optimal window for melanocyte responsiveness to UV photons. Expose skin to 10–15 minutes of midday sun (UV index 6–8) or equivalent tanning bed exposure (8–10 minutes at 0.3W per lamp) starting on day 4 of the loading phase.

Melanogenesis is dose-dependent on both peptide saturation and UV photon energy. UVB radiation (280–320nm wavelength) penetrates the epidermis and directly damages DNA in keratinocytes, triggering p53-mediated signalling that releases paracrine factors (endothelin-1, α-MSH) instructing nearby melanocytes to produce melanin. MT-II amplifies this response by pre-activating MC1R before UV exposure occurs, allowing melanocytes to synthesise eumelanin (brown-black pigment) faster and in greater quantity than they would from UV alone.

Start with 50% of the UV exposure duration you would normally use without MT-II. If you typically tolerate 20 minutes of sun before reddening, start with 10 minutes while on MT-II. The peptide increases photosensitivity. Not through increased UV absorption but through accelerated melanocyte activity, which can outpace the skin's repair mechanisms if overexposed. Erythema (redness) appearing 6–12 hours after UV exposure indicates you exceeded your dose; reduce UV time by 25% in the next session.

Our experience across peptide research applications shows UV timing errors are the primary reason users report 'MT-II not working'. They either expose too early (before MC1R saturation) or skip UV entirely, expecting peptide-only tanning that never occurs.

Melanotan-2 Dosing: Loading vs Maintenance Comparison

Phase	Dose per Injection	Frequency	Duration	UV Exposure Timing	Expected Outcome
Loading Phase	0.25–0.5mg	Daily	5–7 days	Start day 4, 4–6 hours post-injection, 10–15 min	Receptor saturation, initial melanogenesis, baseline tan established
Maintenance Phase	0.5–1mg	Twice weekly (e.g., Mon/Thu)	Ongoing (8–12 weeks typical)	Same day as injection, 4–6 hours after, 15–20 min	Sustained pigmentation, minimal fading between doses
Off-Cycle (Post-Protocol)	None	N/A	4–8 weeks minimum	Optional. Tan fades 30–50% over 6 weeks	Gradual melanin degradation, return to baseline skin tone
Professional Assessment	Loading establishes the tan; maintenance preserves it. Skipping UV during loading wastes the peptide. Exceeding 1mg per injection increases nausea risk without additional tanning benefit.

What If: Melanotan-2 Protocol Scenarios

What If I Don't Have Access to UV Exposure During Loading Phase?

Delay starting MT-II until you have consistent UV access. Injecting the peptide without UV produces MC1R activation but no melanin synthesis. You waste the loading phase and risk receptor desensitisation. Melanocytes upregulate tyrosinase in response to MT-II, but that enzyme has no substrate to act on without UV-induced DNA damage triggering melanin precursor production. If you start loading and then can't access UV for 4–5 days, the receptor saturation you built dissipates, requiring you to restart loading from day 1.

What If I Experience Persistent Nausea Beyond Day 3 of Loading?

Reduce your dose to 0.25mg and extend the loading phase to 10 days instead of increasing to 0.5mg. Nausea is mediated by MC4R activation in the hypothalamus, which has a lower affinity for MT-II than MC1R but still binds at doses above 0.4mg in sensitive individuals. The nausea does not indicate peptide contamination or allergic reaction. It's a predictable off-target effect. Ginger supplementation (500mg) or taking the injection in the evening (so nausea occurs during sleep) helps some users, but dose reduction is the most reliable mitigation.

What If My Skin Turns Red Instead of Tan After UV Exposure?

You exceeded your UV dose relative to your current melanin density. Reduce UV exposure time by 30–40% in the next session and ensure you're injecting 4–6 hours before UV, not immediately before. Erythema (redness) occurs when UVB-induced DNA damage overwhelms the skin's repair mechanisms faster than melanocytes can synthesise protective melanin. MT-II accelerates melanin production but doesn't eliminate the erythemal threshold. It shifts it upward, not removes it. If redness persists beyond 24 hours or blistering occurs, discontinue UV exposure for 48–72 hours while maintaining MT-II injections, then resume at 50% of the previous UV duration.

The Unvarnished Truth About Melanotan-2 Tanning Protocols

Here's the honest answer: MT-II is not a substitute for UV exposure, and it doesn't eliminate the carcinogenic risk of UV radiation. The peptide amplifies your melanocytes' response to UV, which means you can achieve deeper pigmentation with less cumulative UV exposure than natural tanning requires. But you still need UV. Marketing claims that MT-II provides 'sunless tanning' are biochemically inaccurate. Melanogenesis is a UV-dependent process. The peptide optimises the process; it doesn't replace the trigger.

The second uncomfortable truth: MT-II increases photosensitivity during the first 7–10 days of use, which paradoxically raises burn risk if users assume the peptide protects them and extend UV sessions beyond tolerance. A tan provides approximately SPF 2–4 protection (depending on melanin density), but during loading phase before that tan develops, you're more vulnerable to erythema than baseline. Start UV exposure conservatively. The tan builds cumulatively. Rushing the process produces burns, not faster results.

Compounded MT-II from research peptide suppliers like Real Peptides is synthesised to the same amino acid sequence (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂) as pharmaceutical-grade preparations, but it lacks FDA approval as a drug product for human use. It is sold for research purposes. Purity testing via HPLC and mass spectrometry is standard for reputable suppliers, but batch-to-batch consistency and sterility verification are not federally mandated the way they are for approved medications. Use sterile reconstitution technique and source from suppliers who publish third-party purity certificates.

MT-II tanning is a biochemical shortcut to melanogenesis, not a workaround. The UV exposure remains necessary. The peptide makes that exposure more efficient. It does not make it optional.

Most users maintain their MT-II tan for 8–12 weeks before cycling off for 4–8 weeks to allow melanocortin receptors to resensitise. Continuous year-round use is not studied in long-term clinical trials. Pigmentation fades approximately 30–50% over 6 weeks post-cessation as melanin-containing keratinocytes shed through normal epidermal turnover. Some users report mole darkening or new mole appearance during MT-II use, which is consistent with generalised melanocyte activation but requires dermatological monitoring. Any new pigmented lesion should be evaluated, particularly if irregular borders or colour variation develops.

The protocol works. It requires precision. The precision is not optional.

If you're conducting tanning-related peptide research and need verified compounds synthesised through rigorous amino-acid sequencing, explore our verified peptide collection. Every batch undergoes independent purity verification before shipping.

References

Peer-reviewed sources on Melanotan-2 indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-2 for laboratory research use only.

Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN case reports, 2020. PMID 31953620. doi:10.1007/s13730-020-00447-z
Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition. International journal of molecular sciences, 2020. PMID 31968661. doi:10.3390/ijms21020681
The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents. The Journal of pharmacology and experimental therapeutics, 2007. PMID 17567964. doi:10.1124/jpet.107.123091
Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003. PMID 12704398. doi:10.1038/sj.ijo.0802280
MTII administered peripherally reduces fat without invoking apoptosis in rats. Physiology & behavior, 2003. PMID 12834806. doi:10.1016/s0031-9384(03)00118-5
Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain research, 2003. PMID 12834882. doi:10.1016/s0006-8993(03)02683-0

Questions

Melanocortin receptor saturation occurs within 48–72 hours of starting daily injections, but visible tanning requires 5–7 days of combined MT-II loading and UV exposure. The peptide primes melanocytes for pigment synthesis by upregulating tyrosinase, but melanin production only occurs when those activated cells encounter UV radiation. Most users notice initial pigmentation darkening by day 6–8 of the protocol, with full baseline tan established after 10–14 days of maintenance dosing.

No. MT-II activates MC1R receptors on melanocytes, which prepares cells for melanogenesis, but melanin synthesis is UV-dependent. Without UV exposure, the peptide causes receptor activation without pigment production. Marketing claims of ‘sunless tanning’ from MT-II are biochemically inaccurate — the peptide optimises the tanning response to UV, it does not replace the UV trigger. Users who inject MT-II without concurrent UV exposure report no visible tanning.

Melanotan-1 (afamelanotide) is a linear peptide with higher MC1R selectivity and FDA approval for erythropoietic protoporphyria (EPP) treatment under the brand name Scenesse. Melanotan-2 is a cyclic peptide with broader receptor affinity — it binds MC1R (tanning), MC3R (no known effect), MC4R (appetite suppression, nausea), and MC5R (sebum production). MT-II produces faster tanning at lower doses but has higher incidence of nausea and erectile effects in males due to MC4R and MC3R activity. MT-I requires higher doses and longer loading (10–14 days) but has fewer off-target effects.

Research-grade MT-II from peptide suppliers costs approximately $25–$45 per 10mg vial (10–20 doses depending on protocol). It is not FDA-approved for cosmetic tanning in humans and is sold exclusively for research purposes. Possession and personal use fall into a regulatory gray area — MT-II is not a controlled substance under DEA scheduling, but it is not approved for human use by the FDA. Some countries (Australia, UK) classify it as a prescription-only medicine. Pharmaceutical-grade afamelanotide (Melanotan-1) is FDA-approved but available only through specialised clinics for EPP patients at significantly higher cost.

Nausea is the most common adverse effect, occurring in 40% of users during loading phase due to MC4R activation in the hypothalamus. It typically resolves within 72 hours as receptors downregulate. Facial flushing (10–15% of users) occurs 1–2 hours post-injection due to vasodilation and subsides within 30–60 minutes. Spontaneous erections in males (20–30% incidence) result from MC3R and MC4R activity in the hypothalamus and can persist 4–8 hours post-injection. Appetite suppression, mild fatigue, and increased libido are reported but less common. Mole darkening occurs in most users due to generalised melanocyte activation — any new or changing pigmented lesions require dermatological evaluation.

Pigmentation fades approximately 30–50% over 6–8 weeks after discontinuing MT-II as melanin-containing keratinocytes are shed through normal epidermal turnover. The fade rate depends on baseline skin type and cumulative UV exposure during the protocol. Users with naturally higher melanin density (Fitzpatrick types III–IV) retain pigmentation longer than those with lower baseline melanin (types I–II). Some users report residual pigmentation lasting 10–12 weeks post-cessation, but this is not universal. Maintenance dosing (0.5mg once weekly) can extend tan duration indefinitely, though long-term continuous use lacks clinical safety data.

Reconstituted MT-II must be stored at 2–8°C and degrades rapidly at room temperature. Short-term ambient exposure (up to 25°C for 6–8 hours) during travel is tolerable but not ideal. Use an insulin medication cooler (like FRIO wallets, which use evaporative cooling) to maintain refrigeration temperature during transport. Unreconstituted lyophilised MT-II is stable at room temperature for several months and does not require refrigeration until mixed with bacteriostatic water. If traveling for more than 48 hours, consider bringing unreconstituted vials and reconstituting on-site rather than transporting pre-mixed peptide.

Missing one maintenance dose (0.5–1mg twice weekly) does not significantly impact established pigmentation. If you miss a dose by fewer than 3 days, inject as soon as you remember and continue your regular schedule. If more than 4 days have passed, skip the missed dose and resume on your next scheduled injection day — do not double-dose. Pigmentation begins fading after 7–10 days without MT-II, so missing two consecutive maintenance doses may result in noticeable lightening. If you miss an entire week, consider a brief 3-day re-loading phase (0.5mg daily) before returning to twice-weekly maintenance.

MT-II amplifies melanogenesis but does not eliminate UV-induced DNA damage or carcinogenic risk. Individuals with Fitzpatrick skin type I (very fair, always burns, never tans naturally) may achieve some pigmentation with MT-II but remain at elevated risk for UV-induced keratinocyte damage due to low baseline melanin. Anyone with a personal or family history of melanoma, basal cell carcinoma, or squamous cell carcinoma should not use MT-II for cosmetic tanning — the peptide increases mole darkness and may complicate dermatological surveillance. MT-II is contraindicated in individuals with dysplastic nevus syndrome or a history of atypical moles. Consult a dermatologist before beginning any protocol that combines peptide use and deliberate UV exposure.

The most common cause is insufficient or mistimed UV exposure. MT-II primes melanocytes by upregulating tyrosinase, but melanin synthesis only occurs when primed cells encounter UV radiation 4–6 hours post-injection. Users who inject without UV, who delay UV beyond the 6-hour window, or who use inadequate UV intensity (indoor lighting, cloudy days without tanning beds) report minimal tanning. The second cause is underdosing — 0.25mg daily without titration to 0.5mg may produce receptor activation but insufficient tyrosinase upregulation for visible pigmentation. Peptide degradation due to improper storage (room temperature reconstituted vials) also eliminates efficacy without visible indication.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA